|1.||Ewald, Jonathan A: 1 article (08/2012)|
|2.||Jarrard, David F: 1 article (08/2012)|
|3.||Beck, V: 1 article (12/2003)|
|4.||Schulte, H: 1 article (12/2003)|
|5.||von Wietersheim, A: 1 article (12/2003)|
|6.||Kopp, I: 1 article (12/2003)|
|7.||Nass-Griegoleit, I: 1 article (12/2003)|
|8.||Holsteg, K: 1 article (12/2003)|
|9.||Alt, D: 1 article (12/2003)|
|10.||Nill, J: 1 article (12/2003)|
05/01/1983 - "AZQ gave additive effects with tumor irradiation and was equally effective against aerobic and hypoxic cells. "
11/01/1990 - "To assess the response rates and toxicity of AZQ in children with recurrent brain and other malignant solid tumors, a phase II study was implemented by the Pediatric Oncology Group. "
01/01/1990 - "As administered in this study, AZQ has marginal activity and severe myelotoxicity in children with solid tumors."
01/01/1990 - "A phase II study of diaziquone in children with recurrent or progressive solid tumors. "
03/01/1987 - "To test the efficacy and toxicity of AZQ administered by continuous infusion, a phase II multi-institutional trial was undertaken by the Southeastern Cancer Study Group. "
|2.||Brain Neoplasms (Brain Tumor)
12/01/1988 - "A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors."
05/01/1984 - "This study revealed that AZQ enters the CNS and brain-tumor tissue in substantial concentrations and that there is no significant advantage to intracarotid infusion of AZQ."
10/01/1983 - "AZQ is worthy of further studies in patients with primary brain tumors."
01/01/1983 - "In phase I and preliminary phase II trials, diaziquone has demonstrated activity against primary brain tumors. "
11/01/1990 - "We conclude that for selected brain tumors, the rates of objective response and stable disease plus the duration of responses support further assessment of AZQ in combination with other agents. "
|3.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
08/01/1991 - "Because of its activity in ANLL and NHL and its unique toxicity spectrum, high-dose AZQ may improve the efficacy of current BMT preparative regimens without significantly increasing their nonhematopoietic toxicity."
01/01/1986 - "The lack of significant nonhematologic toxicity and the activity in patients with relapsed ANLL render diaziquone of interest as second-line therapy or consolidation therapy in first remission for patients with ANLL."
07/01/1987 - "This study confirms the activity of AZQ when given as a continuous infusion to patients with relapsed acute nonlymphocytic leukemia."
07/01/1987 - "Phase II study of continuous-infusion diaziquone in relapsed/refractory acute nonlymphocytic leukemia."
12/15/1989 - "Diaziquone and 2,2'-anhydro-arabinosyl-5-fluorocytosine for the treatment of children with relapsed or refractory acute nonlymphoblastic leukemia."
01/01/1986 - "Diaziquone given as a bolus has not been effective in patients with relapsed or refractory leukemia. "
08/01/1982 - "For phase II adult leukemia studies using this schedule, it is recommended that the AZQ dose should be 24 mg/m2/d."
01/01/1989 - "In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone."
04/01/1984 - "Subsequently, intraventricular AZQ was administered to a patient with refractory meningeal leukemia. "
12/01/1982 - "Aziridinylbenzoquinone (AZQ) treatment of central nervous system leukemia."
|5.||Breast Neoplasms (Breast Cancer)
02/01/1983 - "Our results indicate that AZQ given on the 5-day schedule is unlikely to be effective in the treatment of refractory breast cancer."
01/01/1988 - "Treatment of metastatic breast cancer with AZQ: a phase II trial."
12/01/2003 - "A systematic, stepwise methodological process according to a level two guideline of the German Association of the Scientific Medical Societies (AWMF) and the Agency for Quality in Medicine (AZQ) was performed with the following elements: 1. Establishing an expert panel, 2. Generating the guideline statements by a formal, consensus based nominal group process, 3. External review process and finding supportive partners for the guideline on women information, 4. Using the guideline for guidelines: implementing the concept in the guideline of early detection of breast cancer in Germany. "
02/01/1983 - "Phase II clinical evaluation of AZQ in metastatic breast cancer."
01/01/1988 - "Seventeen patients with metastatic breast cancer who had failed prior chemotherapy were treated with intravenous AZQ at a dose of 15-20 mg/m2 weekly for four consecutive weeks followed by a two-week rest period. "
|3.||Dimethyl Sulfoxide (DMSO)
|7.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Bone Marrow Transplantation (Transplantation, Bone Marrow)